Esperion Therapeutics Inc (ESPR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Esperion Therapeutics Inc (ESPR) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.29 Million) by net assets ($-451.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Esperion Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Esperion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Esperion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Esperion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Esperion Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Television Media Ltd
SHG:600088
|
-0.005x |
|
Hudson Pacific Properties Inc
NYSE:HPP
|
0.010x |
|
Mako Mining Corp
V:MKO
|
0.146x |
|
Collins Foods Ltd
AU:CKF
|
0.166x |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
-0.095x |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
-0.010x |
|
Pason Systems Inc.
TO:PSI
|
0.044x |
|
Atlantic China Welding Consumables Inc
SHG:600558
|
0.010x |
Annual Cash Flow Conversion Efficiency for Esperion Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Esperion Therapeutics Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see ESPR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-388.72 Million | $-23.65 Million | 0.061x | -79.57% |
| 2023-12-31 | $-454.99 Million | $-135.49 Million | 0.298x | -44.85% |
| 2022-12-31 | $-323.78 Million | $-174.83 Million | 0.540x | -59.69% |
| 2021-12-31 | $-196.94 Million | $-263.81 Million | 1.340x | +51.18% |
| 2020-12-31 | $-96.13 Million | $-85.18 Million | 0.886x | +125.13% |
| 2019-12-31 | $19.95 Million | $-70.34 Million | -3.526x | -87.68% |
| 2018-12-31 | $79.12 Million | $-148.64 Million | -1.879x | -250.11% |
| 2017-12-31 | $244.69 Million | $-131.30 Million | -0.537x | -157.01% |
| 2016-12-31 | $228.60 Million | $-47.73 Million | -0.209x | -57.19% |
| 2015-12-31 | $287.26 Million | $-38.16 Million | -0.133x | +44.60% |
| 2014-12-31 | $133.55 Million | $-32.02 Million | -0.240x | +1.93% |
| 2013-12-31 | $74.09 Million | $-18.11 Million | -0.244x | -139.33% |
| 2012-12-31 | $-17.39 Million | $-10.81 Million | 0.622x | -58.49% |
| 2011-12-31 | $-6.06 Million | $-9.07 Million | 1.497x | +318.37% |
| 2002-12-31 | $38.74 Million | $-26.56 Million | -0.686x | -100.26% |
| 2001-12-31 | $66.50 Million | $-22.77 Million | -0.342x | -29.08% |
| 2000-12-31 | $67.69 Million | $-17.95 Million | -0.265x | +90.49% |
| 1999-12-31 | $2.81 Million | $-7.85 Million | -2.790x | -- |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more